Sort   by:  
 Page size 
Advanced clinical trials investigate the Psilocybe magic mushroom natural product psilocybin as a treatment against major depressive disorder. Currently, synthetic material is used to meet the demand for legitimate pharmaceutical purposes. Here, we report an in vitro approach to biocatalytically pro...
ORGANISM(S): Psilocybe sp. 180 Escherichia coli 
2025-05-05 | PXD061303 | Pride
Effect of psilocybin on visual cortex
Analysis of plasma from two human participants treated with 25 mg oral psilocybin capsules. Blood was collected at baseline, 1 hour, and 2.5 hours after treatment.
ORGANISM(S): Homo sapiens (Human) 
2026-09-08 | PAD000051 | Pride
Effect of psilocybin on visual cortex
ORGANISM(S): Mus musculus 
2025-03-26 | GSE285605 | GEO
Psilocybin prevents chemotherapy-induced peripheral neuropathy via mitochondrial trafficking preservation
gene expression analysis of the rat prefrontal cortex following psilocybin or ketanserin administration
Psilocybin, and other serotonergic psychedelics, have re-emerged as therapeutics for neuropsychiatric disorders, including addiction. Psilocybin induces long-lasting effects on behavior, likely due to its profound ability to alter consciousness and augment neural connectivity and plasticity. Impaire...
ORGANISM(S): Mus musculus 
2022-08-17 | GSE209859 | GEO
Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling complication affecting millions of patients and frequently limiting the delivery of life-saving cancer therapy, with no proven prophylactic options and only modest treatments for established symptoms. Here, we show that as little as tw...
ORGANISM(S): Homo sapiens Mus musculus 
2026-09-04 | GSE333441 | GEO
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
Sort   by:  
 Page size